

- 749 Epidemiology of Measles United States, 1998
- **753** Water Fluoridation and Costs of Medicaid Treatment for Dental Decay — Louisiana, 1995–1996
- 757 Congenital Syphilis United States, 1998
- 761 Multiple Human Exposures to a Rabid Bear Cub
- 761 Outbreak of Poliomyelitis Kunduz, Afghanistan, 1999

#### Epidemiology of Measles — United States, 1998

тм

During 1998, a provisional total of 100 confirmed measles cases was reported to CDC by state and local health departments, representing a record low number of cases and 28% fewer than the 138 cases reported in 1997 (1). This report describes the epidemiology of measles during 1998, which suggests that measles is no longer an indigenous disease in the United States.

#### **Case Classification**

MORBIDITY AND MORTALITY

WEEKLY REPORT

Measles cases among persons who were infected outside the United States are classified as internationally imported cases. Cases among persons who were infected in the United States are classified as indigenous measles cases. Indigenous cases are subclassified into three groups: cases epidemiologically (epi)-linked to importation (a chain of transmission caused by an internationally imported case); imported virus cases (a chain of transmission from which an imported measles virus strain was isolated but a link to an internationally imported case was not identified) (2); and not importation-associated cases (no epidemiologic or virologic association to importation was detected). Internationally imported cases, cases epi-linked to importation, and imported virus cases are all considered importation-associated cases.

Of the 100 cases reported, 26 were internationally imported, and 74 were indigenous. Of the 74 indigenous cases, 45 were importation-associated, and 29 were not importation-associated. The proportion of cases not associated with importation has declined from 85% in 1995, 72% in 1996, 41% in 1997, to 29% in 1998. The 45 importation-associated indigenous cases included 13 epi-linked cases and 32 imported virus cases.

All 32 imported virus cases occurred in an outbreak in Alaska, which started 4 weeks after an imported case of measles was diagnosed in a visitor from Japan. Measles virus isolated from cases in this outbreak was nearly identical to virus circulating in Japan, although no virus was cultured from the imported case and no epidemiologic link between the imported case and the outbreak was detected (3). In addition to the strain isolated from the Alaska outbreak, viral genomic sequencing of specimens from epi-linked cases allowed genotype classification of measles virus strains from six chains of transmission epidemiologically linked to internationally imported cases. Virus strains isolated from cases in New York, Vermont, California, Massachusetts, and Washington matched viral genotypes from Germany, Cyprus, Japan,

#### **U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES**

#### Epidemiology of Measles — Continued

China, and Croatia, respectively. Measles virus was isolated from the Indiana outbreak but genotype information was unavailable from Zimbabwe, the source country of the imported case.

#### Internationally Imported Measles Cases

The 26 internationally imported cases reported in 1998 represent the lowest number of imported cases since the recording of importation status began in 1983. Imported cases from the Americas remained at very low levels, and imported cases from Europe and Asia declined compared with the previous 4 years (Figure 1). India, Japan, Kenya, Pakistan, and Saudi Arabia each were the source of two imported cases. One importation was reported from each of the other countries. Of 26 imported cases, 14 occurred among international visitors and 12 occurred among U.S. residents exposed to measles while traveling abroad.

#### **Geographic Distribution**

During 1998, 28 states and the District of Columbia reported no confirmed measles cases, compared with 21 states in 1997. Eight states accounted for 82% of cases: Alaska (33 cases), Arizona (11), Michigan (10), California (nine), New Jersey (eight), New York (four), Pennsylvania (four), and Indiana (three). In the remaining 14 states, two or fewer cases were reported. Eight states reported indigenous measles cases not associated with importation.

## FIGURE 1. Measles cases, by source of importation and year — United States, 1994–1998



\*Data are provisional.

#### Epidemiology of Measles — Continued

#### **Temporal Patterns of Transmission**

The median number of cases per week was one (range: 0–11). During 35 weeks, all reported measles cases were importation-associated, including 21 consecutive weeks (weeks 25–45) (Figure 2). Half of the indigenous cases that were not importation-associated occurred in two outbreaks: in New Jersey (weeks 13–16) and in Michigan (weeks 20–23).

#### Age and Vaccination Status

The age distribution and vaccination status of U.S. residents with measles differed from those of international visitors. Most U.S. residents with measles had been vaccinated with one or more doses of measles vaccine (53%), and 86% of international visitors with measles were unvaccinated.

#### Outbreaks

Six measles outbreaks\* were reported in 1998, the fewest ever reported to CDC. Outbreaks occurred in Alaska (33 cases), Arizona (11), Michigan (nine), New Jersey (six), Indiana (three), and Pennsylvania (three). The 65 measles cases reported from these outbreaks represented 65% of all cases reported during 1998. The ages of persons with outbreak-associated cases ranged from 5 months to 44 years (median: 15 years).

The largest measles outbreak reported since 1996 occurred in a high school in Anchorage, Alaska; 30 of the 33 cases had received one dose of measles vaccine. A 4year-old unvaccinated Japanese child visiting Anchorage had measles diagnosed 4 weeks before the other cases in the outbreak. No epi-link was reported between this

\*Three or more cases in a single chain of transmission.

## FIGURE 2. Measles cases, by importation status and week of rash onset — United States, 1998



#### Epidemiology of Measles — Continued

case and subsequent cases. However, the genotype of viral RNA collected from outbreak cases was nearly identical to virus circulating in Japan. The interval from the onset of rash in the imported case to the end of the outbreak was 15 weeks (August 10 to November 19, the longest interval of transmission in 1998). As a result of the outbreak, the Alaskan Health Department now requires two doses of measles vaccine for all students in grades K-12 (*3*).Three outbreaks (Arizona, Indiana, and Pennsylvania) were epi-linked to an imported measles case, and two outbreaks (Michigan and New Jersey) were not importation-associated.

Reported by: State and local health depts. Measles Virus Section, Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; Measles Elimination Activity, Child Vaccine Preventable Diseases Br, Epidemiology and Surveillance Div, National Immunization Program; and an EIS Officer, CDC.

**Editorial Note**: Analysis of epidemiologic data for 1998 suggests measles is no longer an indigenous disease in the United States. Most cases reported in 1998 were associated with importation, including the short chains of indigenous transmission of measles that occurred following international importation of measles.

Cases not associated with importation were insufficient to represent a continuous indigenous chain of measles transmission and probably were misclassifications (not measles), associated with undetected imported measles cases, or linked to known imported cases through chains of transmission not detected by the surveillance system. Misclassifications resulting from false-positive laboratory tests are an expected result of intensive investigation for a rare disease using a laboratory test that is not 100% specific.

Some cases may spread from undetected imported cases of measles. Detecting imported cases is difficult. International visitors with measles may leave the country before the rash appears or before they seek medical care. Even when the imported case is detected, it is difficult to detect every case in the chain of transmission, as was seen in the outbreak in Alaska. This highlights the need to obtain viral specimens from every chain of transmission to supplement epidemiologic information.

The largest outbreak in 1998 occurred in a high school without a second dose measles vaccine requirement (3). As of the 1998–99 school year, 55% of U.S. students were required by their states to have two doses of measles vaccine (CDC, unpublished data, 1998). Vaccination of all students with two doses of measles vaccine by 2001, as recommended by the American Academy of Pediatrics (4) and CDC's Advisory Committee on Immunization Practices (5), will reduce future school outbreaks. Completion of this strategy should further decrease the risk for indigenous transmission of measles following importation of the measles virus.

The United States appears to have eliminated measles as an indigenous disease. High measles vaccination coverage and strong surveillance remain critical to preventing international imported measles cases from causing a resurgence of measles in the United States.

#### References

- 1. CDC. Measles-United States, 1997. MMWR 1998;47:273-6.
- 2. Rota JS, Rota PA, Redd SB, Redd SC, Pattamadilok S, Bellini WJ. Genetic analysis of measles viruses isolated in the United States, 1995–1996. J Infect Dis 1998;177:204–8.
- CDC. Transmission of measles among a highly vaccinated school population—Anchorage, Alaska, 1998. MMWR 1999;47:1109–11.

#### Vol. 48 / No. 34

#### MMWR

#### Epidemiology of Measles — Continued

- American Academy of Pediatrics. Measles. In: Peter G, ed. 1997 Red book: report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, Illinois: American Academy of Pediatrics, 1998.
- CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1998;47(no. RR-8).

#### Water Fluoridation and Costs of Medicaid Treatment for Dental Decay — Louisiana, 1995–1996

Treatment costs for dental decay in young children can be substantial, especially if extensive dental procedures and general anesthesia in a hospital operating room (OR) are needed. Because caries in the primary dentition disproportionately affect children from low-income households (*1,2*), the cost for care frequently is reimbursed by state Medicaid programs. To determine whether the average treatment cost for Medicaid-eligible children in Louisiana differed by community fluoridation status, the Louisiana Department of Health and Hospitals (LDHH) and CDC analyzed Medicaid dental reimbursements and Medicaid eligibility records from July 1995 through June 1996 for children aged 1–5 years. Findings suggest that Medicaid-eligible children in communities with fluoridated water to receive dental treatment in a hospital OR, and the cost of dental treatment per eligible child was approximately twice as high.

The Louisiana Bureau of Health Financing provided data on Medicaid dental reimbursements and Medicaid eligibility from July 1995 through June 1996 for children aged 1–5 years and the number of dentists practicing in each parish (county) in 1995. Demographic data for each parish were obtained from the Bureau of the Census (3). The proportion of the population that received optimally fluoridated water in each parish was estimated based on CDC's 1992 fluoridation census (4) and a study by LDHH (LDHH, unpublished data, 1996). A parish was designated as optimally fluoridated (F) if 100% of its population received fluoridated water (optimal level:  $\geq$ 0.7 ppm) in both 1992 and 1996, and nonfluoridated (NF) if 0% received fluoridated water in both years. Of 64 parishes, five F parishes with 38,162 Medicaid-eligible preschoolers and 14 NF parishes with 16,444 Medicaid-eligible preschoolers were included in this analysis. All analyses were conducted at the parish level.

For each F and NF parish, the percentage of Medicaid-eligible children aged 1–5 years who, during the study period, received one or more of the following types of services was calculated: 1) caries-related services (e.g., fillings, crowns, and pulpotomies); 2) examinations or preventive care (topical fluoride or prophylaxis) but no caries-related services; 3) topical fluoride application (with or without caries-related care); and 4) dental care in a hospital OR. The mean value for each of these measures was calculated for F and NF parishes for each of the five ages.

Medicaid reimbursements for dental procedures likely to be associated with treatment for dental caries were totaled for each parish for each age group. If dental care was provided in a hospital, a payment of \$650 (based on estimates from the Louisiana Bureau of Health Financing) was added for OR use and general anesthesia. The average caries-related cost per Medicaid-eligible child in each parish was obtained by di-

#### Dental Decay — Continued

viding parish Medicaid reimbursements by the number of Medicaid-eligible children in the parish in each age group.

For each age group, linear regression was used to examine the association between parish average caries-related cost per Medicaid-eligible child and fluoridation status of the parish. In addition to fluoridation status, per capita income, population, and dentists per 1000 residents were included in the model as dichotomous variables. Independent variables that added no explanatory power were eliminated through backward elimination to obtain the reduced model (5).

Children residing in F parishes were slightly more likely to have received only examinations or preventive services (Table 1). The proportions of children who received topical fluoride were similar, with younger children in F and older children in NF slightly more likely to have received the procedure. For all age groups, the percentage of Medicaid-eligible children who received one or more caries-related procedures was higher in NF parishes.

The difference in treatment costs per Medicaid-eligible child residing in F parishes compared with those residing in NF parishes ranged from \$14.68 for 1-year-olds to \$58.91 for 3-year-olds (Table 2); at all ages, costs were higher in NF than in F parishes. Louisiana Medicaid-eligible children were distributed uniformly by age; the mean difference in treatment costs per eligible preschooler was \$36.28 (95% confidence interval=\$9.69-\$62.87).

Reported by: R Barsley, DDS, Louisiana State Univ, New Orleans; J Sutherland, DDS, L McFarland, DrPH, State Epidemiologist, Office of Public Health, Louisiana Dept Public Health and Hospitals. Surveillance, Investigations, and Research Br, Div of Oral Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

**Editorial Note**: In this analysis of Medicaid claims, more Medicaid-eligible children in NF parishes received caries-related dental treatment and OR-based care at greater cost than did Medicaid-eligible children in F parishes. In 1998, 1.3 million Louisianans received nonfluoridated water from public water systems that served approximately 10,000 customers (S. Hoffman, Office of Public Health Engineering Services, personal communication, 1999), and 3% of the state population were Medicaid-eligible children aged 1–5 years (*3*). These data suggest that at least 39,000 preschoolers in Louisiana could potentially benefit from water fluoridation; the expected annual reduction in their dental treatment costs is \$1.4 million.

The findings in this report are subject to at least four limitations. First, although the analysis showed an association between lower caries-related costs and residence in one of the five F parishes, the analysis did not measure the length or magnitude of the children's exposure to fluoride. Some children classified as residing in NF parishes once may have resided in F parishes and vice versa. It also did not verify that the water systems serving the five F parishes maintained fluoride concentration at the optimal level. However, misclassification of exposure status would be more likely to reduce the observed effect of fluoridation. Second, if access to dental care were better in NF than in F parishes, children with decay who resided in F parishes would be less likely to seek restorative care, resulting in an underestimate of treatment costs in F parishes and an overstatement of water fluoridation's benefits. The observed rates for preventive care in F and NF parishes suggest similar rather than differential access. Furthermore, this analysis controlled for differences in access to dental care. Third, the difference in treatment costs attributable to water fluoridation would be overstated if

TABLE 1. Mean per	centage of	Medicaid-e	eligible childre	n aged 1-	5 years who	received	various o	dental pro	ocedures	s from Ju	ıly
1995 through June	e 1996 and	the mean	caries-related	cost per	eligible child	d, by age	and fluo	ridation a	status ir	n parish	of
residence — Louisia	ana										

1995 th residen	roug	an pe h Jun Louis	rcent e 199 iana	age of 06 and Mean pe	the	mean	carie	d-eligik	ated o	aged cost po	er eli	gible (	cedure	, by a	ge an	nous ( d fluc	dental oridatio	proced on statu	ures fro is in pa	arish of	ental Deca
	Examination or preventive Caries-related procedure procedure Topic					Hospitalized Fopical fluoride application for treatment						Mean caries-related cost   per eligible child				Y   0					
	F* (	n=5)	NF <sup>†</sup>	(n=14)	<b>F</b> *	n=5)	NF† (	n=14)	F* (	n=5)	NF† (	n=14)	<b>F</b> *	(n=5)	NF <sup>†</sup> (	(n=14)	F*	(n=5)	NF† (	n=14)	òn
Age (yrs)	%	(SD <sup>§</sup> )	%	(SD)	%	(SD)	%	(SD)	%	(SD)	%	(SD)	%	(SD)	%	(SD)	%	(SD)	%	(SD)	tinu
1 2	3.3 11.0	(1.2) (3.3)	4.4 15.9	(2.4) (5.8)	8.2 17.8	(7.1) (10.8)	6.3 16.3	(6.2) (8.1)	7.5 19.2	(5.3) (11.2)	5.8 17.5	(5.3) (9.5)	0.2 1.2	(0.3) (1.1)	1.0 4.0	(0.9) (2.0)	\$ 7.4 \$35.3	(\$5.0) (\$18.8)	16.9 \$75.5	(\$13.1) (\$29.9)	ied
3	19.6	(4.0)	31.6	(10.9)	34.0	(7.9)	30.9	(9.2)	38.2	(15.1)	40.9	(13.2)	1.4	(1.1)	5.0	(2.6)	\$53.8	(\$19.0)	\$117.9	(\$42.1)	
4	27.3	(5.0)	34.5	(9.4)	33.2	(6.2)	32.3	(4.8)	44.6	(9.5)	48.6	(12.3)	0.9	(1.3)	3.4	(2.3)	\$52.1	(\$22.7)	\$ 92.3	(\$25.2)	
5	28.6	(5.4)	34.1	(10.2)	28.0	(6.2)	25.8	(4.5)	44.8	(6.4)	43.7	(11.6)	0.2	(0.2)	1.7	(1.1)	\$39.5	(\$10.0)	\$ 71.0	(\$30.6)	

\* Fluoridated parishes. Total number of Medicaid-eligible children aged 1–5 years residing in F parishes was 38,162. <sup>†</sup> Nonfluoridated parishes. Total number of Medicaid-eligible children aged 1–5 years residing in NF parishes was 16,444. § Standard deviation.

#### Dental Decay — Continued

Age (yrs)	Adjusted R <sup>2</sup>	Estimated treatment cost savings associated with water fluoridation	(95% Cl <sup>§</sup> )
1	0.59	\$14.68	\$ 5.58-\$23.77
2	0.27	\$40.17	\$ 9.81-\$70.53
3	0.42	\$58.91	\$19.45-\$98.37
4	0.47	\$36.08	\$11.81-\$60.35
5 All age groups <sup>†</sup>	0.18	\$31.55 \$36.28	\$ 1.79-\$61.31 \$ 9.69-\$62.87

TABLE 2. Results of multivariate regression* analysis: adjusted R <sup>2</sup> and estimated
treatment cost savings associated with water fluoridation for Medicaid-eligible
children aged 1-5 years residing in fluoridated and nonfluoridated parishes, by age —
Louisiana, July 1995–June 1996

\*Controlling for the parish variables of per capita income, population, and number of dentists per 1000 population.

<sup>†</sup>Assumes children are distributed uniformly by age.

<sup>§</sup>Confidence interval.

children in F parishes had more exposure to other sources of fluoride (e.g., toothpaste or topical application in a dental office). Although fluoride toothpaste use could not be determined, toothpastes containing fluoride accounted for >94% of the market in 1984 (6). Different uses of topical applications was probably not a substantial factor because children in F and NF parishes received topical fluoride in the dental office at similar rates. Finally, lower treatment costs associated with water fluoridation should not be generalized to preschoolers from high- and middle-income families because of their lower prevalence of dental caries in primary teeth (1,2).

The lower treatment costs associated with residence in F parishes is a conservative estimate of benefits because the analysis did not consider benefits that accrue to populations other than Medicaid-eligible preschoolers. For this group, however, treatment cost savings associated with fluoridating the 39 NF water systems that serve populations of  $\geq$ 10,000 could be substantial.

In 1996, approximately 50% of Louisiana's population using public water supplies received fluoridated water, a percentage well below the 2000 objective of 75% (objective 13.9) (7). The 1996 assessment of community water fluoridation in Louisiana also found that of 73 water systems adjusting fluoride content in 1986, only 45 were still doing so in 1996 (8). This decline prompted passage of state legislation in 1997 that 1) established a water fluoridation program within LDHH; 2) encouraged fluoridation of public water systems serving at least 5000 households (because the average number of persons per U.S. household in 1996 was 2.66, this equals approximately 13,000 persons [3]); and 3) created a Fluoride Advisory Board to assist in locating public and private funding to cover the costs of initiating water fluoridation in these locations. In addition, LDHH is planning an early intervention program to ensure that infants and toddlers at high risk for early childhood caries are screened and referred for clinical preventive services (e.g., topical fluoride application), prompt treatment of incipient disease, and education of the parent or caregiver.

#### Dental Decay — Continued

#### References

- 1. Kaste LM, Drury TF, Horowitz AM, Beltran E. An evaluation of NHANES III estimates of early childhood caries. J Public Health Dent 1999 (in press).
- 2. Vargas CM, Crall JJ, Schneider DA. Sociodemographic distribution of pediatric dental caries: NHANES III, 1988–1994. J Am Dent Assoc 1998;129:1229–38.
- 3. Bureau of the Census. USA counties 1996. Atlanta, Georgia: Bureau of the Census, US Department of Commerce, Economics and Statistics Administration, Bureau of the Census, 1996.
- CDC. Fluoridation census 1992. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, CDC, 1993.
- 5. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research principles and quantitative methods. Belmont, California: Life-Time Learning Publications, 1982.
- 6. Bohannan HM, Graves RC, Disney JA, et al. Effect of secular decline in caries on the evaluation of preventive dentistry demonstrations. J Public Health Dent 1985;45:83–9.
- US Department of Health and Human Services. Developing objectives for healthy people 2010. Washington, DC: US Department of Health and Human Services, Office of Disease Prevention and Health Promotion, September 1997.
- 8. Sutherland J, Ray TJ. Community water fluoridation in Louisiana: an update. LDA J 1996; 55:16–7.

#### Congenital Syphilis — United States, 1998

Congenital syphilis (CS) occurs when the spirochete *Treponema pallidum* is transmitted from a pregnant woman with syphilis to her fetus. A multiorgan infection, CS may result in a neurologic or musculoskeletal handicap or death in the fetus when not properly treated. Trends in CS rates in women of childbearing age follow by approximately 1 year the rates of primary and secondary syphilis (1). The last national syphilis epidemic, which was followed by a CS epidemic, occurred during the late 1980s and early 1990s. The syphilis rate began to decline in 1991 (2); the CS rate began to decline in 1992 (1). To evaluate CS epidemiology since this decline, CDC analyzed 1998 CS notifiable disease data and assessed rate changes during 1992–1998. This report summarizes the results, which indicate that the CS rate declined 78.2% from 1992 to 1998, and that rates remained disproportionately high in the southeastern United States and among minority racial/ethnic populations.

CS surveillance data were reported to CDC from the 50 states and District of Columbia. For the purpose of public health surveillance, CS is defined as 1) infants manifesting typical signs of CS or in whom *T. pallidum* is identified from lesions, placenta, umbilical cord, or autopsy specimens; 2) infants whose mothers have a syphilitic lesion at delivery; 3) infants born to women with untreated or inadequately treated syphilis before or during pregnancy, and to women whose serologic response to penicillin therapy was not documented, and either a) no examination of the infant was performed radiographically and by cerebrospinal fluid (CSF), or b) one or more radiologic or CSF tests were consistent with CS.\* CS rates per 100,000 live births were determined from state natality data.<sup>†</sup>

<sup>\*</sup>Congenital Syphilis Case Investigation and Report Form 73.126.

<sup>&</sup>lt;sup>†</sup>From the National Center for Health Statistics, Vital Statistics: Natality Tapes 1989–1996.

#### Congenital Syphilis - Continued

In 1998, 801 CS cases were reported for a rate of 20.6 per 100,000 live births (Figure 1). The median state-specific rate of CS was substantially higher in the South (23.0) compared with a median of zero in the Midwest, Northeast, and West<sup>§</sup>. Forty-seven states reported rates below the 2000 goal of 40 per 100,000 (objective 19.4) (*3*) (Table 1); 22 states reported no cases.

Persons of minority race/ethnicity accounted for the highest rates of CS in 1998. Blacks had the highest rate (87.0), followed by Hispanics (27.9), American Indians/Alaska Natives (14.0), Asians/Pacific Islanders (4.9), and non-Hispanic whites (2.9). For 16 persons, race was unknown or categorized "other." CS rates declined for all racial and ethnic groups during 1992–1998 following the decline in primary and secondary syphilis (Figure 1). Asians/Pacific Islanders (82.4%) had the largest percentage decline, followed by blacks (79.5%), Hispanics (78.5%), whites (56.9%), and American Indians/Alaska Natives (11.9%).

In 1998, 73.4% of mothers of infants with CS were aged 20–34 years (median: 27 years). The CS rate was highest for women aged 45–49 years (65.7) and lowest for

FIGURE 1. Congenital syphilis\*, primary and secondary syphilis rates<sup>†</sup>, by year — United States, 1992–1998



\*Per 100,000 live births. \*Per 100,000 population.

758

<sup>&</sup>lt;sup>§</sup> Northeast=Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; *Midwest*=Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; *South*= Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; and *West*=Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

Congenital Syphilis — Continued

State	Cases	Rate	State	Cases	Rate
Alabama	9	14.9	Montana	0	0
Alaska	0	0	Nebraska	0	0
Arizona	25	33.2	Nevada	0	0
Arkansas	30	82.5	New Hampshire	0	0
California	119	22.1	New Jersey	86	75.2
Colorado	1	1.8	New Mexico	0	0
Connecticut	0	0	New York	56	21.2
Delaware	0	0	North Carolina	24	23.0
District of Columbia	8	95.4	North Dakota	0	0
Florida	71	37.5	Ohio	4	2.6
Georgia	14	12.3	Oklahoma	15	32.5
Hawaii	0	0	Oregon	0	0
ldaho	0	0	Pennsylvania	21	14.2
Illinois	71	38.8	Rhode Island	0	0
Indiana	0	0	South Carolina	19	37.2
lowa	0	0	South Dakota	0	0
Kansas	0	0	Tennessee	9	12.2
Kentucky	5	9.5	Texas	102	30.9
Louisiana	8	12.3	Utah	1	2.4
Maine	0	0	Vermont	0	0
Maryland	44	61.5	Virginia	4	4.3
Massachusetts	2	2.5	Washington	1	1.3
Michigan	16	12.0	West Virginia	0	0
Minnesota	0	0	Wisconsin	6	8.9
Mississippi	15	36.6	Wyoming	0	0
Missouri	15	20.3	Total	801	20.6

 TABLE 1. Congenital syphilis cases and rates,\* by mother's state of residence — United

 States, 1998

\*Per 100,000 live births.

women aged 10–14 years (17.9) (age was unknown for two persons). Women aged 35–49 years had a slightly higher rate (23.2) than women aged 10–34 years (20.2).

Of the 801 reported cases, 651 (81.3%) occurred because the mother received no penicillin treatment or inadequate treatment before or during pregnancy; in 233 (35.8%) of these cases, the mother received no prenatal care. Infants of mothers who had an unknown or equivocal response to therapy accounted for 91 (11.4%) of all cases; in 30 of these cases, the infant was evaluated and found to have evidence of CS radiographically or by examination of CSF. The remaining 59 (7.4%) infants were reported to have CS because of inappropriate serologic response to therapy in the mother (4), evidence of treatment failure or reinfection, or other reasons. Of the reported 801 infants, 748 (93.4%) were live born, 45 (5.6%) were stillborn; eight (1.0%) of those born alive were reported to have died, six within the first 2 days of life.

Reported by: State and local health depts. Div of Sexually Transmitted Diseases Prevention, National Center for HIV, STD, and TB Prevention, CDC.

**Editorial Note**: In 1998, CS rates continued a downward trend parallel to the decreased rates for primary and secondary syphilis. Although the South leads other regions in CS reports, the median state-specific rate in this region declined 68.6% since 1992. Historically, the South has had the highest syphilis and CS rates. Factors associated with syphilis include inadequate access to sexually transmitted disease (STD) clinics

#### Congenital Syphilis — Continued

and STD outreach activities, poor interagency coordination, lack of employment opportunities, and discomfort with discussing STDs (5).

Racial/ethnic minorities continue to be affected disproportionally by CS. No biologic association exists between race and the risk for delivering an infant with CS; race serves as a marker for other factors, such as poverty and access to health care, in communities with high syphilis rates (5–7). Individual factors, such as illicit drug use and the wantedness of pregnancy, also influence the chances of a mother delivering an infant with CS.

The findings in this report are subject to at least three limitations. First, the analysis includes inconsistent application of the case definition in some areas. Second, maternal treatment history and infant laboratory data reporting were incomplete at times. Third, the case report form does not include questions about important risk information (e.g., drug use, health insurance, and wantedness of pregnancy), although studies that have collected these data have suggested their importance (*8,9*).

CS surveillance is complicated by difficulty in establishing the diagnosis. Most infants born with CS have no signs of the disease at birth. If untreated, symptoms may begin within 3 months after birth and may include anemia, skin rash, hepatosplenomegaly, and nasal discharge. CS is almost entirely preventable with early prenatal screening and treatment (9). The primary reason that infants were born with CS in 1998 is because mothers with syphilis during pregnancy either received no prenatal care, syphilis serologic testing was performed too late in pregnancy, or mothers were tested but received late or no follow-up.

Community-based organizations, maternal- and child-health programs, and substance abuse agencies can assist in preventing CS by collaborating with health-care providers to encourage pregnant women to obtain prenatal care the first trimester. Health-care providers who perform pregnancy testing where syphilis rates are high also should perform the rapid plasma reagin card test on-site when a woman has a positive pregnancy test and again the third trimester so that results and treatment can be provided immediately. Health-care providers should treat a pregnant woman with syphilis as a medical emergency. Data reported in this study indicate the need to train prenatal health-care providers in recognizing, treating, and preventing CS, and the need to address social problems associated with syphilis as part of the renewed efforts toward its elimination in the United States (*10*).

#### References

- 1. CDC. Sexually transmitted disease surveillance, 1997. Atlanta, Georgia: US Department of Health and Human Services, Public Health Service, September 1998.
- 2. CDC. Primary and secondary syphilis—United States, 1997. MMWR 1998;47:493-7.
- US Department of Health and Human Services. Healthy people 2000: midcourse review and 1995 revisions. Washington, DC: US Department of Health and Human Services, Public Health Service, 1995.
- CDC. 1998 Guidelines for treatment of sexually transmitted diseases. MMWR 1998;47(no. RR-1).
- Thomas JC, Clark M, Robinson J, Monnett M, Kilmarx PH, Peterman TA. The social ecology of syphilis. Soc Sci Med 1999;48:1081–94.
- 6. CDC. Use of race and ethnicity in public health surveillance. MMWR 1993;42(no. RR-10).
- Kilmarx PH, Zaidi AA, Thomas JC, et al. Sociodemographic factors and the variation in syphilis rates among US counties, 1984 through 1993: an ecological analysis. Am J Public Health 1997;87:1937–43.

#### Congenital Syphilis — Continued

- 8. Webber MP, Lambert G, Bateman DA, Hauser WA. Maternal risk factors for congenital syphilis: a case-control study. Am J Epidemiol 1993;137:415–22.
- Southwick KL, Guidry HM, Weldon M, Mertz KJ, Berman SM, Levine WC. An epidemic of congenital syphilis in Jefferson County, Texas 1994–1995: inadequate prenatal syphilis testing after an outbreak in adults. Am J Public Health 1999;89:557–60.
- 10. St. Louis ME, Wasserheit JN. Elimination of syphilis in the United States. Science 1998;281: 353–4.

#### Public Health Dispatch

#### Multiple Human Exposures to a Rabid Bear Cub at a Petting Zoo and Barnwarming — Iowa, August 1999

On August 27, 1999, a black bear cub, approximately 5–6 months old, died after several hours of acute central nervous system symptoms; preliminary test results available on August 28 indicated the bear had rabies. The bear was part of the Swenson's Wild Midwest Exotic Petting Zoo in Clermont, Iowa (northeastern Iowa). At the petting zoo, visitors fed, wrestled, and may have been nipped by the bear. The bear also was taken to an August 14 barnwarming at the Tharp barn in Holy Cross, Iowa (eastern Iowa), where it reportedly nipped people. An estimated 400 people from 10 states (Arizona, California, Florida, Illinois, Iowa, Minnesota, New Mexico, New York, Ohio, and Wisconsin) and Australia had contact with the bear cub at either the petting zoo or the barnwarming during the 28 days before its death, during which the bear may have transmitted rabies virus.

On the basis of telephone calls to petting zoo visitors who signed the guest register and provided contact information, approximately 150 of the 400 persons were exposed to the bear's saliva and need to obtain vaccine and rabies immune globulin. Public health authorities are attempting to contact petting zoo visitors by telephone and the Internet. However, because not all petting zoo visitors signed the register or provided sufficient information to enable health authorities to locate them, state and local health departments are encouraged to ensure local media coverage to alert persons who had contact with the bear after July 30 to the need for exposure assessment. Persons who attended the barnwarming also need to be assessed for prophylaxis.

Information is available from the emergency telephone number of the lowa Department of Public Health: (515) 323-4360.

Reported by: Center for Acute Disease Epidemiology, lowa Dept of Public Health.

Public Health Dispatch

#### Outbreak of Poliomyelitis — Kunduz, Afghanistan, 1999

Since May 10, 1999, 26 cases of acute flaccid paralysis (AFP), including five cases with isolation of wild poliovirus type 1 and one with type 3, have been reported from Kunduz province in northern Afghanistan. Fifteen (54%) case-patients resided in Kunduz city, and the remaining patients resided in the districts surrounding Kunduz. Although the exact causes for the outbreak are not known, the discontinuation of polio

#### Public Health Dispatch — Continued

vaccination activities in mid-1997 in northern Afghanistan because of ongoing civil conflict may have facilitated the outbreak.

AFP surveillance was established in northern Afghanistan in early May 1999 and was instrumental in detecting and reporting AFP cases and collecting stool specimens for virus isolation in the World Health Organization network laboratory in Pakistan. To determine the extent of the outbreak, health facilities and nongovernmental organizations providing health care in northern Afghanistan have been asked to immediately report all suspected AFP cases to the Ministry of Public Health. To control the outbreak, a large-scale house-to-house vaccination campaign with oral poliovirus vaccine (OPV), targeting the >130,000 children aged <5 years in the province, was conducted during August 7–12, 1999. A second round is scheduled for September 7–12, 1999.

During 1997–1999, Afghanistan conducted three National Immunization Days (NIDs)\*, providing an additional six doses of OPV to most children aged <5 years; however, none of these NIDs covered every district. Because of the conflict, the 1998 NIDs were not conducted in Kunduz and other areas of northern Afghanistan. In 1999, NIDs were conducted in May (round 1) and June (round 2) in all areas of the country and are scheduled again for October (round 3) and November (round 4). These scheduled NIDS will attempt to ensure complete coverage of the country.

Control of the outbreak is complicated by the several thousand internally displaced persons who are now moving into the Kunduz area, following renewed fighting north of Kabul. Efforts are under way to provide OPV vaccine to the children of these displaced families. Two rounds of mopping-up vaccination with OPV in the border districts of Tajikistan and Uzbekistan will be conducted in October and November to minimize any risk for poliovirus importation to these neighboring countries.

Reported by: Ministry of Public Health, Kabul, Afghanistan; Afghanistan Country Office, World Health Organization, Islamabad, Pakistan. Eastern Mediterranean Regional Office, World Health Organization, Alexandria, Egypt. Vaccines and Other Biologicals Department, World Health Organization, Geneva, Switzerland. Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; Vaccine Preventable Disease Eradication Div, National Immunization Program, CDC.

<sup>\*</sup>Mass campaigns over a short period (days to weeks) in which two doses of oral poliovirus vaccine are administered to all children in the target group (usually aged 0–4 years) regardless of previous vaccination history, with an interval of 4–6 weeks between doses.



#### FIGURE I. Selected notifiable disease reports, comparison of provisional 4-week totals ending August 28, 1999, with historical data - United States

\*Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

#### TABLE I. Summary — provisional cases of selected notifiable diseases, United States, cumulative, week ending August 28, 1999 (34th Week)

				0 4000
		Cum. 1999		Cum. 1999
Anthrax Brucellosis* Cholera Congenital rubella syndrome Cyclosporiasis* Diphtheria Epoophalitic: California*		- 31 4 3 38 2	HIV infection, pediatric* <sup>§</sup> Plague Poliomyelitis, paralytic Psittacosis* Rabies, human Rocky Mountain spotted fever (RMSF)	86 3 - 15 - 348
Encephalitis:	California* eastern equine* St. Louis* western equine*	15 2 -	Streptococcal disease, invasive Group A Streptococcal toxic-shock syndrome* Syphilis, congenital <sup>¶</sup> Tetanus	1,464 28 118 19
Ehrlichiosis Hansen Disea Hantavirus pu Hemolytic ure	human granulocytic (HGE)* human monocytic (HME)* se* ilmonary syndrome* <sup>†</sup> emic syndrome, post-diarrheal*	95 23 57 14 51	Toxic-shock syndrome Trichinosis Typhoid fever Yellow fever	78 6 198 -

-: no reported cases

\*Not notifiable in all states.

\*Not notifiable in all states.
 <sup>†</sup> Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (NCID).
 <sup>§</sup> Updated monthly from reports to the Division of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention (NCHSTP), last update July 25, 1999.
 <sup>¶</sup> Updated from reports to the Division of STD Prevention, NCHSTP.

	Escheric coli 0157					erichia				
	AI	DS	Chla	mydia	Cryptosp	oridiosis	NET	ISS	PH	LIS
Reporting Area	Cum. 1999†	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998
UNITED STATES	26,427	30,497	371,677	378,852	1,015	2,467	1,623	1,726	1,107	1,428
NEW ENGLAND	1,298	1,094	12,455	13,264	63	108	182	231	193	195
Maine N.H.	43 31	22 25	193 615	644 631	17	24 12	18 23	25 31	- 23	- 36
Vt.	6	17	310	271	18	18	20	10	12	7
Nass. R.I.	842	506 92	6,053 1,504	5,453 1,520	20	49 5	102	8	98	111
Conn.	306	432	3,780	4,745	-	-	Ŭ	46	54	40
MID. ATLANTIC	6,746	8,609	44,532	39,467	204	374	94	186	37	67
N.Y. City	846 3,592	4,821	21,963	17,321	78 107	142	83 5	128	13	12
N.J.	1,278	1,563	6,456	7,638	9	15	6	47	23	42
	1,030	1,21/	10,113 55 241	14,508	10	-	228	200	1 221	13
Ohio	262	459	16,106	17,341	30	50	129	79	96	49
Ind.	224	376	6,667	6,839	18 17	41	42	64	27	38
Mich.	360	389	13,851	13,590	31	24	64	64	41	44
Wis.	90	134	U	8,893	-	297	N	Ν	34	61
W.N. CENTRAL Minn	611 105	579 102	21,373 4 434	22,306 4 529	88 14	185 62	355 133	255 98	195 103	235 108
lowa	55	51	1,615	2,601	29	43	68	62	37	42
Mo. N. Dak	295 4	280 4	8,595 325	8,085 646	17 12	17 22	29 8	31 7	36 1	44 13
S. Dak.	13	13	1,035	1,027	5	19	34	17	13	21
Nebr. Kans.	45 94	56 73	2,060 3.309	1,821 3.597	10 1	18 4	69 14	23 17	- 5	- 7
S. ATLANTIC	7,281	7,496	80,700	72,803	216	172	194	137	115	117
Del. Md	95 793	104 899	1,779	1,655	- 11	2 12	5 11	- 20	3	1 12
D.C.	274	568	0,510 N	3,120 N	7	4	-	1	-	-
Va. W. Va	372 40	617 60	9,666 1 148	8,313 1 558	12	6 1	45 8	- 7	37 4	42
N.C.	482	535	14,812	14,528	6	-	40	38	38	35
S.C.	683 1 091	501 730	6,968 19 477	12,049 14 876	- 95	- 65	17 18	5 50	13	5
Fla.	3,451	3,482	19,932	14,698	85	82	50	16	20	17
E.S. CENTRAL	1,145	1,267	27,658	26,360	17	19	83	85	42	49
Ky. Tenn.	442	431	4,631 9,133	4,137 8,612	5 6	8 6	41	26 35	26	30
Ala.	287	372	8,221	6,609	4	-	17	19	13	17
WISS.	240	3 787	52 519	7,002 57 403	2 41	5 781	4 52	5 61	64	73
Ark.	107	136	3,915	2,473	1	6	9	7	7	8
La. Okla	541 74	651 224	7,726 5 418	9,299 6 477	21 4	11	3 15	3 11	11 9	4
Tex.	2,136	2,776	35,460	39,154	15	764	25	40	37	56
MOUNTAIN Mont	1,021	1,028	20,193	21,205	64 10	91	147	234	75	185
Idaho	16	19	1,101	1,277	7	16	18	26	8	17
Wyo.	4 107	209	445	428 5 226	-	- 11	5	49	5	53
N. Mex.	65	166	1,748	2,337	25	35	7	43	3	15
Ariz.	518 84	384	8,338	7,460	9	14	23 25	31 45	14	23 21
Nev.	132	159	1,894	2,203	5	7	11	11	2	13
PACIFIC	3,748	4,399	57,006	62,074	226	275	188	247	155	261
Wash. Oreg.	218 118	267 129	7,718 3.779	7,258 3.478	- 79	31	59 41	42 70	64 37	74 73
Calif.	3,348	3,876	42,559	48,520	147	241	85	132	47	103
Alaska Hawaii	13 51	17 110	1,217	1,240	-	- 3	- 3	3	- 7	- 11
Guam	5	-	226	261	-	-	N	Ν	-	-
P.R. VI.	821 19	1,243 19	UN	UN	-	-	5 N	3 N	U	U
Amer. Samoa	-	-	Ü	Ü	-	-	N	N	Ŭ	Ŭ
C.N.IVI.I.	-	-	N	N	-	-	N	N	U	U

TABLE II. Provisional cases of selected notifiable diseases, United States,weeks ending August 28, 1999, and August 29, 1998 (34th Week)

U: Unavailable N: Not notifiable C.N.M.I.: Commonwealth of Northern Mariana Islands -: no reported cases

\*Individual cases may be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the

Public Health Laboratory Information System (PHLIS). <sup>†</sup>Updated monthly from reports to the Division of HIV/AIDS Prevention–Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, last update July 25, 1999.

	Gonorrhea		Hep C/N	atitis A,NB	Legior	nellosis	Lyme Disease		
Reporting Area	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	
UNITED STATES	200,535	224,572	2,225	2,124	515	845	5,933	9,429	
NEW ENGLAND Maine N.H. Vt.	3,788 15 64 34	3,855 41 58 24	59 2 - 4	47 - 2	41 4 4 8	49 1 3 4	1,789 22 5 9	2,936 56 28 9	
Mass. R.I. Conn.	1,680 382 1,613	1,384 238 2,110	50 3 -	42 3	16 3 6	24 8 9	678 284 791	595 308 1,940	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	24,548 3,837 9,463 3,621 7,627	24,154 4,616 7,717 4,998 6,823	97 62 - 35	148 75 - 73	105 33 9 5 58	211 69 29 13 100	3,069 2,206 25 124 714	4,996 2,641 156 864 1,335	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	36,849 9,798 3,676 13,383 9,992 U	43,727 11,073 4,038 14,287 10,371 3,958	1,157 1 25 548 582	477 7 5 34 320 111	131 55 21 10 42 3	287 95 54 35 55 48	78 53 14 10 1 U	568 27 24 11 12 494	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak.	9,089 1,664 452 4,448 31 120	10,817 1,686 860 5,716 51 158	85 4 - 72 -	26 7 7 9 -	31 4 11 11 2	43 3 5 11 3	89 45 10 16 1	133 96 21 9 -	
Nebr. Kans.	939 1,435	742 1,604	3 6	2 1 70	3	15 6	6 11 600	3 4	
Del. Md. D.C. Va.	58,696 1,110 5,886 1,259 6,327	909 5,741 2,941 5,506	146 1 34 - 10	70 - 8 - 10	80 8 16 1 17	100 9 27 6 16	690 19 492 3 76	613 50 439 4 43	
W. Va. N.C. S.C. Ga. Fla.	311 12,942 3,700 13,070 14,091	557 12,580 7,587 13,117 11,729	13 29 15 1 43	4 17 3 9 19	N 13 7 18	N 8 7 7 20	14 52 5 - 29	8 41 3 5 20	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	22,229 2,030 7,380 7,315 5,504	25,224 2,402 7,504 8,472 6,846	194 12 83 1 98	186 16 104 4 62	31 14 14 3	47 23 12 5 7	69 6 36 16 11	68 16 29 13 10	
W.S. CENTRAL Ark. La. Okla. Tex.	28,868 2,002 6,054 2,665 18,147	35,317 2,646 8,053 3,530 21,088	144 8 100 12 24	328 13 21 8 286	3 1 2	14 1 2 8 3	21 3 - 4 14	17 6 3 2 6	
MOUNTAIN Mont. Idaho	5,806 26 52	5,869 29 120	98 4 6	288 7 85	33 - -	47 2 2	11 - 2	9 - 3	
Wyo. Colo. N. Mex. Ariz. Utah Nev.	14 1,473 379 2,982 121 759	18 1,323 578 2,708 157 936	31 16 7 21 5 8	68 18 69 4 19 18	9 1 5 12 6	1 12 2 9 16 3	3 - 1 - 3 2	1 - 2 - 3	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	10,662 1,330 525 8,369 201 237	14,942 1,247 518 12,635 213 329	245 12 15 218 -	554 13 13 474 54	60 10 N 49 1	47 9 N 36 1 1	117 4 10 103 -	89 5 12 71 1	
Guam P.R. V.I. Amer. Samoa C.N.M.I.	32 182 U U	38 264 U U 26	- - U U -	- U U -	- U U	2 U U	- - U U -	U U U	

## TABLE II. (Cont'd.) Provisional cases of selected notifiable diseases, United States,<br/>weeks ending August 28, 1999, and August 29, 1998 (34th Week)

N: Not notifiable U: Unavailable -: no reported cases

					Salmonellosis*						
	Ма	laria	Rabies,	Animal	NE	TSS	PH	LIS			
Reporting Area	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998			
UNITED STATES	789	895	3,699	4,917	20,641	24,678	17,161	21,746			
NEW ENGLAND	30	42	537 100	945 150	1,054	1,623	1,220	1,525			
N.H.	2	3	32	52	89	122	96	166			
Vt. Mass	3 12	- 16	70 120	42 324	60 753	83 890	51 677	68 900			
R.I.	3	2	68	60	65	85	48	31			
MID. ATLANTIC	0 174	262	683	1.087	2.407	4.179	2.202	4.045			
Upstate N.Y.	47	55	492	757	727	1,004	714	933			
N.Y. City N.J.	29	31	118	136	332	867	442	1,141 888			
Pa.	21	24	73	194	527	988	409	1,083			
E.N. CENTRAL Ohio	74 17	102 9	81 27	82 45	2,761 760	4,142 992	2,145 561	3,097 804			
Ind.	10	10	-	7	300	463	264	375			
Mich.	26	33	46	27	627	770	600	688			
WIS.	2	7	3	522	38	646 1 477	321	352			
Minn.	21	29	400	89	418	355	469	413			
lowa Mo.	12 12	7 12	102 10	116 28	170 431	254 421	121 573	204 573			
N. Dak.	-	2	104	102	32	43	4	54			
S. Dak. Nebr.	-	- 1	2	121	68 131	65 118	- 58	28			
Kans.	4	7	76	70	195	221	144	188			
S. ATLANTIC Del.	233	1//	1,362 30	1,633	4,859 90	4,544 47	3,366	3,620			
Md.	67 13	55 12	271	326	545 53	566	542	558			
Va.	51	37	344	396	851	650	638	584			
W. Va. N.C.	1 15	1 14	79 284	59 428	105 721	106 643	105 770	104 808			
S.C.	8	4	102	98	321	298	262	308			
Fla.	56	31	130	131	1,489	1,344	288	321			
E.S. CENTRAL	18	20	189	196 27	1,161	1,333	620	1,055			
Tenn.	7	10	64	107	319	364	325	481			
Ala. Miss.	4 1	4 2	94	60 2	360 214	422 290	242 53	372 78			
W.S. CENTRAL	10	18	77	25	1,414	2,246	1,674	1,894			
Ark. La.	1 6	1 6	14	25	305 159	292 262	116 370	232 458			
Okla. Tex	2	2	63	-	228 722	277 1 415	130 1.058	121 1.083			
MOUNTAIN	29	44	130	153	1,950	1,571	1,333	1,411			
Mont. Idaho	4	- 7	46	35	39	60 76	1	37			
Wyo.	1	-	32	49	29	42	22	39			
Colo. N. Mex.	11 2	12 11	1 6	22	513 238	380 194	519 174	363			
Ariz.	5	8	39	31	601 246	480	508	484			
Nev.	1	5	2	3	118	129	53	128			
PACIFIC Wash	172 17	172 16	152	264	3,590 430	3,563 292	3,232 576	3,558 447			
Oreg.	15	13	1	1	312	201	371	239			
Alaska	132	2	144	240	2,579	2,894 31	2,075	2,071			
Hawaii	7	4	-	-	237	145	204	182			
Guam P.R.	-	2	45	34	20 251	21 466	-	-			
V.I. Amer, Samoa	U	U	U	U	-	-	-	-			
C.N.M.I.	-	-	-	-	-	23	-	-			

## TABLE II. (Cont'd.) Provisional cases of selected notifiable diseases, United States, weeks ending August 28, 1999, and August 29, 1998 (34th Week)

N: Not notifiable U: Unavailable -: no reported cases \*Individual cases may be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

		Shige	llosis*		Syp	hilis			
	NE	TSS	PH	LIS	(Primary &	Secondary)	luberculosis		
<b>Reporting Area</b>	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999†	Cum. 1998†	
UNITED STATES	8,448	12,541	3,792	7,108	4,012	4,588	9,059	10,559	
NEW ENGLAND	352	301	280	267	34	48	264	272	
N.H.	4 11	10	- 8	- 15	-	1	12	6	
Vt.	4	5	3	-	3	4	1	3	
Mass. R.I.	316	198	221	187	22	30	28	36	
Conn.	U	56	39	53	8	11	56	78	
MID. ATLANTIC	517	1,658	280	1,352	142	200	1,592	1,885	
N.Y. City	179	529	82	516	67	28 41	864	915	
N.J.	103	495	98 58	511 214	32	68	339	399	
F.N. CENTRAI	1.375	1.842	704	961	749	677	801	1.077	
Ohio	314	364	78	85	66	93	164	161	
Ind. III.	141 614	115 992	42 354	33 800	258 296	125 280	34 377	104 517	
Mich.	258	174	165	4	129	130	187	223	
VVIS.	48	197	65	39	U 80	49	39	/2	
Minn.	158	207	494	264	6	92 6	280 98	294 98	
lowa Mo	20	50	16	35	7	- 72	29 117	24	
N. Dak.	485	6	- 208	3	-	-	2	6	
S. Dak. Nebr	10 38	29	5	20 16	-	1	9 12	14	
Kans.	32	235	28	21	10	8	19	35	
S. ATLANTIC	1,550	2,734	325	856	1,338	1,681	1,920	1,818	
Del. Md.	10 96	15	5 25	18 46	6 247	470	12	26 196	
D.C.	38	15	-	-	33	59	32	72	
va. W. Va.	/5 7	128	35	62 7	113	104	30	29	
N.C.	144	214	63	100	341	473	299	271	
Ga.	135	764	42 37	191	225	185	194 405	325	
Fla.	959	1,349	115	391	212	176	646	510	
E.S. CENTRAL	814 180	568 86	390	375 45	744	789 73	597 111	764 113	
Tenn.	505	107	345	158	425	376	228	243	
Ala. Miss.	74 55	337 38	40 5	168 4	152 104	179 161	202 56	264 144	
W.S. CENTRAL	1,114	2,375	868	761	571	677	1,004	1,538	
Ark.	57	133	21	35	40	81	110	76	
Okla.	357	214	102	56	136	34	86	117	
Tex.	624	1,877	673	477	274	286	808	1,218	
MOUNTAIN Mont.	566	/4/	311	485	153	164	271 10	358	
Idaho	17	13	7	11	1	1	14	7	
vvyo. Colo.	2 99	1 118	73	100	- 1	8	I U	4 41	
N. Mex.	80	187	40	91 250	10	19	42	41	
Utah	38	28	-	250	2	3	27	42	
Nev.	42	20	6	8	6	12	27	73	
PACIFIC Wash	1,415 68	1,621 86	140 65	1,635 103	192 48	260 23	2,324 126	2,553 170	
Oreg.	53	93	53	88	6	3	64	83	
Calif. Alaska	1,269	1,411 4	-	1,411	135 1	232	1,985	2,148	
Hawaii	25	27	22	31	2	1	110	117	
Guam	7	29	-	-	1	1	-	59	
V.I.	-	43	-	-	U	132 U	41 U	00 U	
Amer. Samoa C.N.M.I.	-	- 16	-	-	U -	U 161	U	U 74	

#### TABLE II. (Cont'd.) Provisional cases of selected notifiable diseases, United States, weeks ending August 28, 1999, and August 29, 1998 (34th Week)

 N: Not notifiable
 U: Unavailable
 -: no reported cases

 \*Individual cases may be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

 \*Cumulative reports of provisional tuberculosis cases for 1999 are unavailable ("U") for some areas using the Tuberculosis Information System (TIMS).

	H. influ	uenzae,	Hepatitis (Viral), by type					Measles (Rubeola)					
	inva	asive		A		В	Indi	genous	Imp	orted*	То	tal	
Reporting Area	Cum. 1999 <sup>†</sup>	Cum. 1998	Cum. 1999	Cum. 1998	Cum. 1999	Cum. 1998	1999	Cum. 1999	1999	Cum. 1999	Cum. 1999	Cum. 1998	
UNITED STATES	793	761	9,701	14,738	4,174	6,375	-	37	1	18	55	50	
NEW ENGLAND	59	49	142	197	67	131		6		4	10	3	
Maine N.H.	5 14	2	5 10	15 9	1 10	2 11	U	-	U	- 1	- 1	-	
Vt.	5	5	6	13	2	4	-	-	-	-	-	1	
Mass. R.I.	22 1	31 2	54 13	80 11	31 23	50 43	-	5	-	2	7	2	
Conn.	12	1	54	69	-	21	U	1	U	1	2	-	
MID. ATLANTIC	125	119	634	1,143	471	846		-		2	2	13	
Upstate N.Y. N.Y. City	61 28	39 35	166 162	232 396	130 139	163 292	U -	-	U -	2	2	2	
N.J.	35	38	57	229	40	152	U	-	U	-	-	8	
	126	101	249	286	162	239	U	-	U	-	-	3	
Ohio	46	42	453	2,256	415	939 53	-	-	-	-	-	15	
Ind.	20	31	74	105	32	76	U	1	U	-	1	3	
Mich.	9	40 5	967	1,246	316	285	-	-	-	- 1	- 1	10	
Wis.	-	5	26	149	1	363	U	-	U	-	-	1	
W.N. CENTRAL	59 24	69 54	502	1,063	217	268	-	-	-	-	-	-	
lowa	6	2	92	368	27	45	-	-	-	-	-	-	
Mo. N Dak	21	8	282 1	483	123	158 4	-	-	ū	-	-	-	
S. Dak.	1	-	8	21	1	1	-	-	-	-	-	-	
Nebr. Kans	3 4	- 5	40 34	20 78	11 25	11 19	-	-	-	-	-	-	
S ATLANTIC	187	139	1 292	1 226	798	667		1	1	4	5	8	
Del.	-	-	2	3	-	-	-	-	-	-	-	1	
Md. D.C.	48 4	43	243 37	267 42	118 14	97 9	ū	-	ū	-	-	1	
Va.	14	13	103	153	63	72	-	1	-	2	3	2	
vv. va. N.C.	6 28	5 22	26 103	3 74	17 147	5 149	-	-	-	-	-	-	
S.C.	3	3	28	22	53	25	U	-	U	-	-	-	
Ga. Fla.	49 35	30 23	314 436	356	105 281	122 188	U -	-	1	2	2	2	
E.S. CENTRAL	51	42	280	274	312	333	-	-	-	-	-	2	
Ky.	5	7	50	22	29	33	-	-	-	-	-	-	
Ala.	29 15	23 10	39	50	56	47	-	-	-	-	-	1	
Miss.	2	2	49	45	58	67	-	-	-	-	-	-	
W.S. CENTRAL	41	39	1,648	2,606	491	1,416	-	5	-	3	8	-	
La.	7	17	59	45	72	65	U	-	U	-	-	-	
Okla. Tex	28 4	20	336 1 216	385 2 111	94 292	59 1 226		- 5	-	- 3	- 8	-	
MOUNTAIN	69	85	905	2,772	416	565	-	2	-	-	2	-	
Mont.	1	-	16	72	16	5	-	-	-	-	-	-	
Idaho Wyo.	1	- 1	31 4	186 27	20 9	23 3	- U	-	Ū	-	-	-	
Colo.	10	17	156	186	62	69	-	-	-	-	-	-	
N. Mex. Ariz.	18 30	4 42	33 544	108 1,354	136	221 133	-	- 1	-	-	- 1	-	
Utah	6	3	35	138	24	51	-	1	-	-	1	-	
Nev.	2	18	86	151	37	60	-	-	-	-	-	-	
Wash.	76 3	88 6	2,438	3,751 742	987 44	1,210 65	-	- 22	-	4	26	9 1	
Oreg.	30	36	174	290	58	127	-	9	-	-	9		
Alaska	35	38 1	2,032	2,666	12	999 10	-	- 12	-	4	-	1	
Hawaii	3	7	10	38	10	9	-	1	-	-	1	-	
Guam PR	- 1		2	1	2	2	U	1	U	-	1	-	
r.n. V.I.	U	∠ U	U	46 U	U	U	U	Ū	Ū	Ū	Ū	Ū	
Amer. Samoa C.N.M.I.	U	U	U	U 3	U	U 45	U	U	U	U	U	U	

### TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending August 28, 1999, and August 29, 1998 (34th Week)

N: Not notifiable U: Unavailable -: no reported cases

\*For imported measles, cases include only those resulting from importation from other countries.

 $^{+}$ Of 155 cases among children aged <5 years, serotype was reported for 77 and of those, 19 were type b.

	Mening Dise	Meningococcal Disease		Mumps			Pertussis		Rubella			
Reporting Area	Cum.	Cum.	1999	Cum.	Cum.	1999	Cum.	Cum.	1999	Cum.	Cum.	
UNITED STATES	1,654	1,868	2	218	476	73	3,381	3,730	2	1333	329	
NEW ENGLAND	84	82		4	4	9	404	649		7	38	
Maine N.H.	5 12	5 10	U -	- 1	-	U 2	- 69	5 51	U -	-	-	
Vt. Mass	4 47	1 38	-	1	- 3	2	38 266	59 496	-	- 7	- 8	
R.I.	4	3	-	-	-	-	20	7	-	-	1	
MID. ATLANTIC	12	25 197	-	- 25	171	-	613	393	-	21	29 143	
Upstate N.Y.	40	51	U	6	3	U	527	206	U	17	113	
N.J.	39	47	U	-	6	U	12	11	U	1	13	
Ρα. Ε Ν. CENTRAI	33 259	75 300	0	16 27	9 59	U 1	64 292	153 463	U	3	1	
Ohio	111	107	-	11	21	1	149	169	-	-	-	
lnd. III.	37 76	52 80	U -	3	5 9	U -	37 46	71 47	U -	1 1	-	
Mich. Wis.	34 1	37 24	- U	7	22 2	- U	33 27	45 131	- U	-	-	
W.N. CENTRAL	179	162	-	10	24	17	171	290	-	83	32	
Minn. Iowa	38 32	28 27	-	1 4	12 8	16 1	78 26	168 57	-	5 28	-	
Mo. N Dak	69 3	60 3	-	2	3	-	36	22	-	2	2	
S. Dak.	10	6	-	-	-	-	5	8	-	-	-	
Nebr. Kans.	9 18	27	-	3	-	-	21	22	-	48	30	
S. ATLANTIC	291	305	1	38	32	11	261	186	1	32	13	
Md.	43	24	-	3	-	-	70	32	-	1	1	
D.C. Va.	1 35	26	U -	2 8	- 5	U -	- 13	1 9	U -	-	-	
W. Va. N.C.	4 32	12 46	-	- 8	- 9	-	2 63	1 74	- 1	31	- 9	
S.C.	33	45	U	3	5	U	13	22	Ŭ	-	-	
Fla.	49 88	83	1	11	12	11	25 71	34	-	-	3	
E.S. CENTRAL	115	131	-	8	13	2	64 16	86 26	-	1	1	
Tenn.	47	48	-	-	1	2	29	26	-	-	1	
Ala. Miss.	27 19	38 23	-	/	7 5	-	15 4	20 4	-	1	-	
W.S. CENTRAL	143	215	1	29	44	8	120	233	-	7	87	
La.	30 34	42	Ū	3	7 5	U	3	42	U	-	-	
Okla. Tex.	25 54	30 117	- 1	1 25	32	- 8	12 91	20 168	-	- 7	- 87	
MOUNTAIN	101	105	-	12	30	24	384	647	-	16	5	
Mont. Idaho	2 8	4 7	-	- 1	- 4	-	2 93	5 168	-	-	-	
Wyo. Colo	3 27	5 21	U	- 3	1 6	U 3	2 122	8 172	U	- 1	-	
N. Mex.	13	17	Ν	Ň	Ň	18	80	76	-	- 12	1	
Utah	13	10	-	5	4	3	50 52	46	-	1	2	
Nev. PACIEIC	6 328	6 371	-	3	10 99	- 1	3 1 072	32 783	- 1	1 19	1 10	
Wash.	51	51	-	2	7	1	540	221	-	-	5	
Oreg. Calif.	57 211	62 252	N -	N 52	N 72	-	27 479	57 480	-	- 4	3	
Alaska Hawaii	5 4	2 4	-	1 10	2 18	-	4 22	12 13	- 1	- 15	2	
Guam	1	2	U	1	2	U	1	-	U	-	-	
P.R. V.I.	5 U	9 U	Ū	Ū	2 U	Ū	16 U	4 U	Ū	- U	Ū	
Amer. Samoa C.N.M.I.	U -	U -	U U	U -	U 2	U U	U -	U 1	U U	U -	U -	

# TABLE III. (Cont'd.) Provisional cases of selected notifiable diseases preventable<br/>by vaccination, United States, weeks ending August 28, 1999,<br/>and August 29, 1998 (34th Week)

N: Not notifiable U: Unavailable -: no reported cases

	All Causes, By Age (Years)						P&I <sup>†</sup>		All Causes, By Age (Years)					P&I <sup>†</sup>	
Reporting Area	All Ages	>65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	>65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn. Cambridge, Mass. Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Mass New Haven, Conn. Providence, R.I. Somerville, Mass. Springfield, Mass. Waterbury, Conn.	458 132 38 11 23 U 22 22 22 22 22 22 35 60 8 260 8 219 50	320 80 26 8 20 U 17 10 20 23 48 5 13 12 38	82 28 7 2 3 U 3 2 - 8 8 3 9 3 6	35 13 4 1 - U 2 - 1 2 - 3 3 6	11 6 1 - U - 1 1 - 1 1 - 1	10 5 - - - - 1 4 - -	30 8 1 U 2 1 1 5 - 1 9	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla. Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, Fla. Tampa, Fla. Washington, D.C. Wilmington, Del. E.S. CENTRAL	888 U 130 97 149 U 366 68 48 88 174 98 U 651	571 U 76 52 105 U 27 46 31 66 115 53 U 426	199 U 34 26 28 U 5 16 9 15 34 32 U 141	69 U 13 9 U 2 2 4 1 7 8 U 53	23 U 4 3 U - 2 1 - 7 2 U 21	26 U 3 2 4 U 2 2 3 6 1 3 U 6	40 8 5 8 U 1 5 4 8 1 U 29
MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.	2,111 49 U 38 11 40	1,441 35 U 23 5 32	404 9 U 0 3 3	173 2 U 5 3 1	50 2 U 2 3	41 1 U 2 -	73 1 U 2 5	Birmingnam, Aia. Chattanooga, Tenn. Knoxville, Tenn. Lexington, Ky. Memphis, Tenn. Mobile, Ala. Montgomery, Ala. Nashville, Tenn.	177 97 71 58 U 89 44 115	115 67 48 33 U 59 31 73	40 17 14 16 U 19 9 26	13 6 7 4 U 7 4 12	6 5 1 U 4 - 4	1 1 4 U -	7 4 3 U 2 3 10
Jersey City, N.J. New York City, N.Y. Newark, N.J. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Schenectady, N.Y. Scranton, Pa. Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	55 1,042 U 19 484 37 28 129 U 35 99 32 13 U	29 700 U 14 336 24 21 95 U 28 72 72 18 9 U	8 218 U 1 82 8 4 25 U 5 17 11 4 U	5 87 U 37 3 7 U - 4 3 - U	2 21 U 13 1 2 U 1 3 - U	11 15 U 1 6 1 - U 3 - U	23 U 20 1 6 U 1 8 5 U	W.S. CENTRAL Austin, Tex. Baton Rouge, La. Corpus Christi, Tex. Dallas, Tex. El Paso, Tex. Houston, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La. San Antonio, Tex. Shreveport, La. Tulsa, Okla.	1,506 72 51 34 242 55 106 326 72 142 241 50 115	989 50 34 25 140 42 72 211 40 83 169 36 87	305 17 9 5 53 9 15 78 22 27 40 9 21	120 1 5 4 32 4 11 23 4 15 17 2 2	49 1 6 1 8 2 13 11 2 4	43 3 2 11 7 6 4 4 4 1 1	61 2 2 4 19 2 8 13 8
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Garv, Ind.	1,340 44 U 128 122 174 109 U 34 70 20	938 30 31 U 85 74 122 76 U 25 48 14	250 10 9 0 30 31 18 0 6 10 2	83 3 1 2 11 14 9 U 2 7 3	31 1 2 3 5 3 U 1 3 1	38 1 2 9 3 2 3 U - 2	73 4 U 12 2 10 5 U 4	MOUNTAIN Albuquerque, N.M. Boise, Idaho Colo. Springs, Colo Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, Utah Tucson, Ariz.	835 105 U 58 99 213 28 77 20 94 141	540 67 U 36 70 121 21 49 16 62 98	164 24 11 16 57 2 12 3 16 23	84 10 5 9 21 3 10 - 13 13	24 4 U 3 2 7 - 3 - 2 3	22 U 3 2 6 2 3 1 1 4	43 2 U 2 10 13 2 8 4
Garan Rapids, Mich Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohio	. 45 131 28 116 47 59 48 69 52	14 32 87 20 89 31 36 39 55 44	2 9 26 5 20 11 14 4 8 6	3 2 9 2 3 4 4 2 4 1	1 3 1 2 1 2 2	1 6 2 3 1 2 1	1 3 4 13 2 2 1 7 2	PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawaii Long Beach, Calif. Los Angeles, Calif. Pasadena, Calif. Portland, Oreg. Sacramento, Calif.	1,233 10 80 20 72 74 313 17 119 U	873 8 57 16 54 49 229 11 83 U	227 1 15 4 17 12 53 6 19 U	81 1 6 - 7 19 - 13 U	24 - - 1 4 5 - 2 U	28 2 - 2 7 - 2 0	81 7 1 3 8 23 4 4 U
W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans. Kansas City, Mo. Lincoln, Nebr. Minneapolis, Minn. Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	575 49 20 114 43 176 89 U 84 U	412 33 16 U 83 29 127 63 U 61 U	109 10 20 11 33 18 U 16 U	30 3 2 0 6 3 10 5 0 1 0 1 0	14 2 - 2 - 4 2 U 4 U	9 1 2 2 1 U 2 U 2 U	38 4 1 9 - 12 4 U 8 U	San Diego, Calif. San Francisco, Calif San Jose, Calif. Santa Cruz, Calif. Seattle, Wash. Spokane, Wash. Tacoma, Wash. TOTAL	122 125 27 116 58 80 9,597 <sup>¶</sup>	80 U 96 24 80 36 50 6,510	22 U 14 3 26 15 20 1,881	9 U 11 7 3 5 728	4 U 2 2 4 247	7 U 4 1 2 1 223	9 U 2 2 5 4 468

## TABLE IV. Deaths in 122 U.S. cities,\* week ending August 28, 1999 (34th Week)

U: Unavailable -: no reported cases \*Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. \*Pneumonia and influenza. \*Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. Total includes unknown ages.

## Contributors to the Production of the *MMWR* (Weekly) Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H.

**State Support Team** Robert Fagan Jose Aponte Gerald Jones David Nitschke Carol A. Worsham

**CDC Operations Team** Carol M. Knowles Deborah A. Adams Willie J. Anderson Frederick Browder Patsy A. Hall Kathryn Snavely

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/ or from CDC's file transfer protocol server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H. Acting Deputy Director for Science and Public Health, Centers for Disease Control and Prevention Stephen M. Ostroff, M.D.	<ul> <li>Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.</li> <li>Editor, <i>MMWR</i> Series John W. Ward, M.D.</li> <li>Managing Editor, <i>MMWR</i> (weekly) Karen L. Foster, M.A.</li> </ul>	Writers-Editors, MMWR (weekly) Jill Crane David C. Johnson Teresa F. Rutledge Caran R. Wilbanks Desktop Publishing Morie M. Higgins Peter M. Jenkins					
☆U.S. Government Printing Office: 1999-733-228/08019 Region IV							